CEM has signed an exclusive licensing agreement with SpheriTech Ltd, UK to manufacture and sell their range of SpheriTide® -based resins.
SpheriTide has unique properties that provide benefits toward the production of higher purity peptides. CEM is in the process of completing the manufacturing facility for this resin, which will be located at the Company's World Headquarters in North Carolina. Product shipments are expected to begin in the second half of this year.
Commenting on the agreement, Michael J. Collins, president and CEO of CEM Corporation, said, "We are very pleased to have this agreement with SpheriTech, as it will allow us to fully commercialize the SpheriTide resin. Based on our initial evaluation of the resin, and the results we observed for a wide range of peptides, we believe this resin represents a major technological breakthrough and will have a significant impact on peptide synthesis in the future."
"The manufacturing facility is being completed and will be operational in the next few months. We expect the resin to have applications for both the research and process scale markets. We are very excited to be pursuing this new opportunity and look forward to bringing it to market later this year," Collins concluded. In the short term, SpheriTide resin can be obtained through SpheriTech or CEM.
Don Wellings, CEO of SpheriTech commented, "We believe CEM is the ideal company to commercialize the SpheriTide resin, as they are well known as innovators in the field of peptide synthesis. Their microwave synthesizers have dramatically impacted the field in the past few years. I sincerely believe that microwave-based peptide synthesis is scalable and there is no doubt that CEM is perfectly placed to do this. Their new instruments are already making great inroads to this. I am confident CEM will be successful in commercializing the SpheriTide resin and SpheriTech looks forward to working with them."